Saturday, March 20, 2010

“Conference at Lander brings international focus (The Index-Journal)” plus 2 more

“Conference at Lander brings international focus (The Index-Journal)” plus 2 more

Conference at Lander brings international focus (The Index-Journal)

Posted: 18 Mar 2010 11:37 PM PDT

[fivefilters.org: unable to retrieve full-text content]

Lander University will host a Peace Studies Conference sponsored by the Greenwood and Lander chapters of People to People International (PTPI) from 9 a.m. to 2:30 p.m. today. The program, which is free and open to the public, will be at locations in Lander's Grier Student Center.

Scientific Data Relating to Cinryze(TM) (C1 Esterase Inhibitor [Human]) Presented at First International Congress of ... (redOrbit)

Posted: 19 Mar 2010 08:17 AM PDT

Posted on: Friday, 19 March 2010, 07:45 CDT

FLORENCE, Italy and EXTON, Pa., March 19 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of two abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.

Cinryze was approved by the U.S. Food and Drug Administration in October 2008 for routine prophylaxis against hereditary angioedema (HAE) attacks in adults and adolescents. Cinryze is not approved in the European Union or any of its member states.

"We are honored to be presenting HAE data at this important meeting," commented Peter Wijngaard, senior director, clinical development and European medical affairs, ViroPharma Europe. "ViroPharma is committed to raising awareness of HAE and educating healthcare professionals that may not have had any experience diagnosing and treating this rare disease."

The following abstracts from studies supported by Lev Pharmaceuticals, now ViroPharma Biologics, Inc., a fully-owned subsidiary of ViroPharma, were presented:

Poster Session 22: Phase 3 Results of Cinryze as Prophylactic and Acute Treatment of HAE

  • In an abstract entitled, 'Safety and Efficacy of Nanofiltered C1 Inhibitor Concentrate for Acute and Prophylactic Treatment of Hereditary Angioedema due to C1 Inhibitor Deficiency,' Dr. Joshua Jacobs described two double-blind randomized placebo-controlled multi-center studies to determine the efficacy and safety of nanofiltered C1 inhibitor (C1-INH; Cinryze);
  • One trial evaluated prophylactic treatment with C1-INH to prevent attacks. The second trial examined the use of C1-INH for the treatment of acute attacks of hereditary angioedema due to C1 inhibitor deficiency;
  • Cinryze is not approved for acute attacks of HAE.

Poster Session 23: Prophylactic Therapy Considerations in Hereditary Angioedema

  • In an abstract entitled, 'When Should Prophylactic Therapy be Considered for Hereditary Angioedema?', Dr. Richard Gower described how a literature review, guideline analysis from other countries, an expert panel meeting, and consensus development were conducted in order to develop therapy considerations for prophylaxis of HAE in the U.S.;
  • The abstract suggested that patients with frequent HAE attacks, severe attacks, past laryngeal attacks, excessive loss of work or school, significant anxiety and poor quality of life could be considered for prophylaxis therapy, especially for those that fail, are intolerant, have adverse events or are not candidates for androgens;
  • This abstract was the result of a consensus group on the treatment considerations for patients with HAE, which was paid for and organized by Lev Pharmaceuticals.

About Cinryze(TM) (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency.

The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,000 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: http://www.haea.org/.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated


Source: PR Newswire

More News in this Category

Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction.

Students ready for international travel (Hinton Parklander)

Posted: 19 Mar 2010 04:33 PM PDT

Posted 10 hours ago

By Rhys Kelso

Hinton's version of the popular television show, The Amazing Race, ran March 18 at Harry Collinge High School.

Although it may sound like fun the idea for the game is to prepare students for international travel. Two groups of students will be making trips to Greece and Japan this year, but before they left they got a little taste of what travelling in foreign countries will be like.

The idea to start the Amazing Race came from John Griffiths two years ago.

"We found that there were some kids who weren't prepared to travel," said Laurie Folliot, who will take a group of students to Japan.

The idea of the Amazing Race is to take the kids through routine things that will happen while travelling.

The students went through a number of tests. Including running to catch a train with all their luggage, going through airport security and making sure they can describe what is in their luggage.

Folliot said it is important for the kids to think about the trip before they leave.

"In the past we have had kids without watches," she said. "We are always on a schedule and always need to know what time it is."

In addition to preparing the kids for international travel Folliot said it gets the kids excited about the trip.

There are 11 students who will travel to Greece for 12 days. Cathy Thomas will lead the group in a jammed packed schedule. The students will spend five days in and around Athens.

Advertisement

The students will then get to visit the islands for five days. The stops include Mykonos, Santorini, Rhodes and a stop in Turkey. The trip to Greece will teach the kids about what they are learning in social studies.

"The trip ties nicely into social studies," said Thomas. "They can see the growth of democracy and take a look at the European Union."

The group will also have a stop in London on their way back to Hinton.

In total eight students will visit Japan along with three adults including Folliot. It will also be a busy 13 days for the students. The trip starts with four days in Wanouchi, Hinton's sister town. The students will then take trips to Osaka, Hiroshima, Kyoto and Tokyo.

The students will get a chance to stay with host families for the four days they are in Wanouchi and learn about Japanese culture.

Folliot, who teaches Japanese at Harry Collinge, said the Japan trip is unique in that every two years the students go are different.

"There is some flexibility in the trip that let the students pick some things they want to see," she said.

One of the spots that the students will get to visit this time is an anime studio. The students will get a tour of Studio Ghibli, where anime is made.

No matter what trip it is, the students at Harry Collinge will learn a lot about different cultures on this trip.

Folliot said the community deserves a lot of credit for what the students will get to experience.

"We always have to fundraise for these trips," she said. "And we never have a problem fundraising. We owe a big thank you to the community for that. We couldn't do this without the fundraising."

Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)